A Novel and Expanding SARS-CoV-2 Variant, B.1.526, Identified in New York

Medini K. Annavajhala[1*], Hiroshi Mohri[2*], Pengfei Wang[2], Manoj Nair[2], Jason E. Zucker[1], Zizhang Sheng[2], Angela Gomez-Simmonds[1], Anne L. Kelley[1], Maya Tagliavia[1], Yaoxing Huang[2], Trevor Bedford[3], David D. Ho[1,2,4#], Anne-Catrin Uhlemann[1#]

[1] Division of Infectious Diseases, Department of Internal Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA
[2] Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA
[3] Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
[4] Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.

* Medini K. Annavajhala and Hiroshi Mohri contributed equally to this work.
# David D. Ho and Anne-Catrin Uhlemann contributed equally to this work.

Address correspondence to au2110@cumc.columbia.edu or dh2994@cumc.columbia.edu.

Summary

Recent months have seen surges of SARS-CoV-2 infection across the globe along with

considerable viral evolution[1-3]. Extensive mutations in the spike protein may threaten

efficacy of vaccines and therapeutic monoclonal antibodies[4]. Two signature mutations of

concern are E484K, which plays a crucial role in the loss of neutralizing activity of

antibodies, and N501Y, a driver of rapid worldwide transmission of the B.1.1.7 lineage. Here,

we report the emergence of a novel variant lineage B.1.526 that contains E484K and its

alarming rise to dominance in New York City in recent months. This variant is partially or

completely resistant to two therapeutic monoclonal antibodies in clinical use. It is also less

susceptible to neutralization by convalescent plasma or vaccinee sera, posing a modest

antigenic challenge. The B.1.526 lineage has now been reported from all 50 states in the US

and numerous other countries. B.1.526 has rapidly replaced non-variant lineages in New

York, with an estimated transmission advantage of 35%. Although B.1.526 initially outpaced

B.1.1.7 in the region, its growth has slowed concurrent with the rise of B.1.1.7. In states

surrounding New York, B.1.526 continues to increase where B.1.1.7 has not yet reached

dominance, persistently replacing non-variant lineages. Such transmission dynamics,

together with the relative antibody resistance of its E484K sub-lineage, would warrant

consideration of B.1.526 as a SARS-CoV-2 variant of concern.

Main

While evolution of SARS-CoV-2 was deemed to be slow at the beginning of the global pandemic[5], at least four major variants of concern have emerged over the past six months[1-3,6]. These lineages are each characterized by numerous mutations in the spike protein, raising concerns that they may escape from therapeutic monoclonals and vaccine-induced antibodies. The hallmark mutation of B.1.1.7, a SARS-CoV-2 variant of concern that emerged in the UK, is N501Y located in the receptor-binding domain (RBD) of spike[1]. This variant is seemingly more transmissible and virulent[7-9], perhaps due to a higher binding affinity of N501Y for ACE2[10] or a greater propensity to evade host innate immune responses[11]. Two other variants of concern, B.1.351 (first detected in South Africa)[2] and P.1 (first described in travelers from Brazil to Japan)[12,13], share the N501Y mutation with B.1.1.7 but also contain an E484K substitution in RBD[2,3]. Epidemiological evidence suggests that P.1 emerged as part of a second surge in Manaus, Brazil despite a high pre-existing SARS-CoV-2 seroprevalence in the population[14]. Reinfections with P.1, as well as with another related Brazilian variant P.2 that also harbors E484K, have been documented[15,16]. Another variant of concern is the B.1.617.2 lineage that recently emerged from India[6].

Our previous study on B.1.351 demonstrated that this variant is refractory to neutralization by a number of monoclonal antibodies directed to the top of RBD, including several that have received emergency use authorization[4]. Moreover, this variant was markedly more resistant to neutralization by convalescent plasma and vaccinee sera. Importantly, these effects were in part mediated by the E484K mutation. These finding are worrisome in light of recent reports that three vaccine trials showed a substantial drop in efficacy in South Africa[17-19]. Likewise, P.1 was also relatively resistant to antibody neutralization, although not as severely[20]. To systematically screen our patient population in Northern Manhattan for B.1.351 and other E484K variants, as well as B.1.1.7, we implemented a rapid PCR-based screen for signature mutations combined with genomic surveillance.

Rapid screening for signature SARS-CoV-2 mutations

We first developed rapid PCR-based single-nucleotide-polymorphism assays to search for N501Y and E484K mutations (see schematic in Extended Data Fig. 1) in clinical samples known to be positive for SARS-CoV-2 and stored in the Columbia University Biobank, a biorepository of

SARS-CoV-2 patient specimens from hospitals and outpatient clinics within our medical system.

Patient and clinical testing information was extracted from the COVID-Care database[21]. Between

November 1, 2020 and May 1, 2021, 3,433 SARS-CoV-2-positive nasopharyngeal swabs were

available through the Columbia University Biobank for our study (Extended Data Fig. 2). We first

screened 2,174 samples collected between November 1, 2020 and March 5, 2020 for the two

signature mutations E484K and N501Y. There were 741 samples which were non-typeable and

showed no signal in either genotyping assay. We identified 155 samples with E484K (10.8% of

1,433 typeable samples) and 41/1,433 (2.9%) with N501Y. Only one sample contained both

mutations. The earliest case with E484K was collected in mid-November 2020. Subsequently,

there was a substantial increase in the proportion of E484K among PCR-screened cases over time

(Fig. 1a), from 2.0% at the end of 2020 to 24.3% between February 21st and March 5th, 2021, the

final two weeks of targeted PCR genotyping. Viruses harboring N501Y also increased over time,

from the earliest detection in mid-January to 5.3% of screened isolates by the beginning of March.

Genomic surveillance of SARS-CoV-2

We next performed untargeted whole genome nanopore sequencing of nasopharyngeal samples

collected throughout the study period with Ct ≤ 35. We successfully obtained 1,210 SARS-CoV-2

whole genomes. This represents 70.4% of all samples with Ct values of 30 or below and 14.0% of

samples with Ct values between 30 and 35 (Extended Data Fig. 2). Sequencing results verified the

E484K and N501Y substitutions in all samples identified by our screening PCR assays. Amongst

PCR-screened cases with N501Y, 21/30 (70.0%) of sequenced N501Y isolates were identified as

belonging to the B.1.1.7 lineage. One sample which harbored both N501Y and E484K based on

our screening assay was identified as B.1.351. However, quite unexpectedly, the large majority of

PCR-screened cases with E484K (n=85/112, 75.9%) fell within a single lineage, B.1.526,[22]

recently labeled the Iota variant by the WHO[23].

Analysis of the entire collection of CUIMC genomic sequences (Fig. 1b) shows that over the past

few months, SARS-CoV-2 variants (including B.1.526, B.1.1.7, and more recently P.1) now

comprise two-thirds of all sequenced isolates, replacing the vast majority of non-variant lineages

(Fig. 1b). The proportion of cases caused by B.1.526, including the B.1.526-S477N and B.1.526-

L452R sub-lineages, rose rapidly from late 2020 through February 2021, and has remained at

approximately 40-50% of all sequenced cases from March to May 2021, despite a concurrent

increase in B.1.1.7. In fact, during the months of December and January when the prevalence of

B.1.1.7 was still negligible (Fig. 1b, marking under horizontal axis), the frequency of all viruses

in the B.1.526 lineage rose from <5% to 50% while the frequency of non-variant viruses declined

from >95% to 50% (Fig. 1b, where white blank space represents non-variant viruses). Calculations

using these numbers in a head-to-head comparison and an established mathematical method[24]

indicate that B.1.526 has a growth advantage of ~5% per day. Likewise, fitting a logistic regression

model to 478 individual observations from the extended timeframe of November 2020 through

January 2021 shows that B.1.526 has a similar growth advantage of 4.6% per day (95% CI 2.8–

6.5% per day). Given that the serial interval for SARS-CoV-2 transmission is about 7 days[25] in the

absence of any intervention, these results suggest that B.1.526 is ~35% more transmissible than

non-variant viruses. This is certainly a cause for concern.

Signature mutations of the B.1.526 lineage

We identified signature spike-protein mutations in the B.1.526 lineage by comparing all genomes

generated as a part of this study. In Figure 1c, all unique patterns of S-gene mutations in our

collection are displayed. Phylogenetic examination showed that the B.1.526 lineage is comprised

of two closely related sub-lineages harboring either E484K (B.1.526-E484K; defined as Pangolin

lineage B.1.526) or S477N (B.1.526-S477N; Pangolin lineage B.1.526.2) (Fig. 1c). In addition,

the sub-lineage B.1.526.1, which harbors the L452R substitution, has been more recently defined

(referred to in this study as B.1.526-L452R). Both B.1.526-E484K and B.1.526-S477N share

characteristic spike-protein mutations L5F, T95I, D253G, D614G, and either A701V or Q957R

along with either E484K or S477N. Non-spike mutations widely shared by B.1.526-E484K and

B.1.526-S477N isolates include: T85I in ORF1a-nsp2; L438P in ORF1a-nsp4, a 9bp deletion

Δ106-108 in ORF1a-nsp6; P323L in ORF1b-nsp12; Q88H in ORF1b-nsp13; Q57H in ORF3a; and

P199L and M234I in the N gene. While B.1.526-L452R isolates shared a number of mutations

across the genome in ORF-1ab, ORF-3ab, ORF-8, and N, it does not share spike mutations with

B.1.526-E484K and B.1.526-S477N except for D614G, which is ubiquitous in presently

circulating SARS-CoV-2 lineages.

To further investigate the evolutionary history of B.1.526, we performed phylogenetic analyses on

genomes in this collection and in GISAID harboring the 9bp deletion Δ106-108 in ORF1a-nsp6,

along with mutation A20262G that uniquely defines the parent clade containing B.1.526 and

related viruses (Fig. 2a). We observed a stepwise emergence of the key lineage-defining mutations,

with T95I, D253G, and L5F appearing in the earliest phylogenetic nodes. Isolates subsequently

branched into four sub-lineages, with two major groups B.1.526-E484K and B.1.526-S477N

containing A701V, with a smaller sub-lineage B.1.526-S477N containing Q957R. The B.1.526-

L452R lineage also emerged in parallel, as a distinct branch from other B.1.526 lineages.

Fig. 2b displays the localization of B.1.526-E484K and B.1.526-S477N signature spike mutations

within the S protein. D253G resides in the antigenic supersite within the N-terminal domain[26],

which is a target for neutralizing antibodies[27], whereas the E484K is situated at the RBD interface

with the cellular receptor ACE2. The A701V mutation near the furin cleavage site is also shared

with variant B.1.351.

Antibody neutralization of B.1.526

The impact of the signature S protein mutations in B.1.526 on antibody neutralization was first

assessed using vesicular stomatitis virus (VSV) based pseudoviruses as previously described[4,27].

Pseudoviruses containing S477N or E484K alone and all five signature mutations (L5F, T95I,

D253G, A701V, and E484K or S477N), termed NYΔ5(E484K) or NYΔ5(S477N), were

constructed and subjected to neutralization by 12 monoclonal antibodies including 5 with

emergency use authorization, 20 convalescent plasma, and 22 vaccinee sera. The specifics of these

monoclonal antibodies and clinical specimens were previously reported[4]. As shown in Extended

Data Fig. 3a, the neutralizing activity of 12 monoclonal antibodies covering a range of epitopes on

RBD was essentially unaltered against the S477N and NYΔ5(S477N) pseudoviruses, showing that

this mutation has no discernible antigenic impact, as was confirmed using convalescent plasma

and vaccinee sera (Extended Data Fig. 3b). However, against E484K and NYΔ5(E484K)

pseudoviruses, the activities of several antibodies were either impaired or lost, including

REGN10933 and LY-CoV555 that are already in clinical use (Fig. 3a). Likewise, neutralizing

activities of convalescent plasma or vaccinee sera were lowered by 4.1-fold or 3.3-3.6-fold,

respectively, against NYΔ5(E484K) (Fig. 3b) but not against NYΔ5(S477N) (Extended Data Fig.

3b). Neutralization studies of the authentic B.1.526-E484K virus yielded similar results, although

the magnitude of resistance to convalescent plasma or vaccinee sera was slightly lower at 2.6-fold

or 1.8-2.0-fold, respectively (Fig. 3b). A comparative analysis with other variants of concern (Fig.

3c) showed that such risks are likely lower than B.1.351 and closer to P.1. Overall, these results

demonstrate the need to modify our antibody therapy and to monitor the efficacy of current

vaccines in regions where B.1.526-E484K is prevalent.

Clinical comparisons of patients infected with E484K and B.1.526 versus non-variant viral

strains

Patients with E484K variant viruses were comparable in gender, age, race and ethnicity to those

with SARS-CoV-2 strains not harboring either E484K or N501Y (Extended Data Table 1). Patients

with E484K SARS-CoV-2 were more likely to live in New York City and Yonkers versus

elsewhere (p=0.017). E484K-positive patients had a higher rate of diabetes mellitus (32.2 vs

24.1%, p=0.045). The highest level of care required and the need for oxygen supplementation were

comparable between groups. Notably, the cycle threshold (Ct) values for E484K isolates were

significantly lower than isolates not harboring E484K (mean 29.49 vs 30.71, p=0.013), indicating

a modestly higher viral load in these variant samples. Comparison of cases of B.1.526-E484K

versus those with non-variant lineages[28] similarly showed no significant differences in

demographic characteristics. B.1.526-E484K was also associated with a significantly higher

proportion of patients with diabetes mellitus (30.8 vs 21.7%, p=0.014) as well as higher BMI (28.4

versus 26.5 kg/m^2, p=0.008). We also found a lower cycle threshold value associated with B.1.526-

E484K (27.33 vs 28.31 in non-variant lineages, p=0.041). Notably, a significantly higher

proportion of patients B.1.526-E484K were admitted to the hospital or presented to the emergency

department, and a lower proportion received only outpatient care (p=0.041).

Surge of B.1.526 across New York and the U.S.

Prevalence of the novel variant B.1.526 has surged alarmingly in our hospital catchment area (Fig.

4a) and throughout New York State (Fig. 4b) since its emergence in late 2020, replacing non-

variant lineages and initially outpacing B.1.1.7. A multinomial logistic regression model

describing the concurrent growth rates of these two lineages shows that starting in mid-April 2021,

B.1.1.7 surpassed B.1.526 due to a slightly higher fitness, with estimated growth rates in New

York State of 5.3% per day for B.1.1.7 (95% CI 5.0–5.7%) and 3.4% per day for B.1.526 (3.2–

3.6%) (Fig. 4b). These estimates suggest a fitness advantage of B.1.526 over existing non-variant

lineages of 22–25% over a serial interval of 7 days[24,25] during a period when multiple variants are

competing simultaneously. Furthermore, the estimates also suggest a fitness advantage of B.1.1.7

over existing non-variant lineages of 35–40%, as well as a fitness advantage of B.1.1.7 over

B.1.526 of 12–15%. As shown in Figs. 4a and 4b, both lineages grew quickly, but once they

reached a high frequency of circulating viruses, the competition between them caused the growth

of B.1.1.7 to slow and B.1.526 to decline.

Frequency trajectories of B.1.1.7 and B.1.526 across states (Fig. 4c, Extended Data Fig. 4) show

two general patterns: (1) initial rapid increase of both lineages until the proportion of other lineages

had been eclipsed, followed by decline of B.1.526 seen in New York and in several neighboring

states; and (2) rapid growth and resulting dominance of B.1.1.7 preventing the further rise of

B.1.526. The dynamics between these two lineages is further shown in Fig. 4d, which plots the

logistic growth rate of B.1.526 against the frequency of B.1.1.7, again at the state-level. At lower

frequencies of B.1.1.7, all states have a similarly rapid growth of B.1.526 as it replaces non-variant

lineages. As B.1.1.7 increases in frequency, however, it slows the growth of B.1.526, again

indicative of a slightly higher fitness for B.1.1.7. At a minimum, B.1.526 is rising rapidly where

B.1.1.7 is not dominant and, in several states, has continued to grow at a similar pace as B.1.1.7

(Extended Data Fig. 4).

Phylogeographic analysis of viruses designated as belonging to the B.1.526 lineage shows

ancestral viruses originating in New York in August 2020, diversifying within the state, and then

dispersing to other states (Figs. 4e and 4f). State-level genomic data show that B.1.526 is

concentrated primarily in New York and surrounding states, including New Jersey and Rhode

Island (Extended Data Fig. 4). This suggests that B.1.526, and B.1.526-E484K in particular, is

now widespread in the region, the original epicenter of COVID-19 in the US[29,30], although the

lineage has also grown in states outside the Northeastern US (e.g., North Carolina). By the end of

April 2021, the geographic makeup of B.1.526 within the US has become quite diverse, and the

lineage has emerged and expanded in multiple states across the country (Fig. 4f). Of particular

concern is the rise of B.1.526 over the past six months across the United States (Extended Data

Fig. 4), as well as its international spread.

Discussion

Here we report the emergence of a novel SARS-CoV-2 lineage, B.1.526, and its alarming surge in

New York during the second wave of the COVID-19 pandemic (Fig. 1b). Neutralization studies

on B.1.526-E484K demonstrate that the activities of several antibodies were either impaired or

lost, including two (Ly-CoV555 and REGN10933) already in clinical use (Fig. 3a). Furthermore,

neutralizing activities of convalescent plasma or vaccinee sera were lower against B.1.526

harboring E484K (Fig. 3b). These findings are of concern, and it will be important to monitor the

antigenic impact of this variant on re-infection or vaccine breakthrough in the future. The S477N

mutation, a key signature of another B.1.526 sub-lineage, on the other hand, did not have an impact

on antibody neutralizing (Extended Data Fig. 3).

Several limitations of our study need to be considered. This was a single-center genomic survey

representing patients presenting to a hospital system and may not have fully captured patients with

milder disease. However, we note that our results are comparable to genomic data released by

public health laboratories in the region and further incorporate all publicly available data for

phylogeographic context and growth rate calculations. As in all genomic surveillance studies, we

predominantly sequenced samples with a Ct of < 30 but covered a high proportion of samples

throughout the study period. In addition, our PCR screen allowed us to obtain unbiased estimates

of E484K and N501Y prevalence early on in the study. PCR approaches may be increasingly

warranted now for continued surveillance, as new infection rates are lower in the US and Ct values

are higher during non-surge periods. Lastly, transmissibility estimates based on observed

prevalence are imperfect as they reflect observed growth rates rather than intrinsic transmissibility

of the virus.

Taken together, our findings underscore the importance of the E484K mutation, which has

emerged in at least 246 different lineages of SARS-CoV-2[31], a real testament to convergent

evolution. This raises the possibility that E484K can rapidly emerge in multiple clonal

backgrounds and may warrant targeted screening for this key mutation in addition to robust

genomic surveillance programs. However, B.1.526 is one of the few lineages with E484K that has
risen to prominence. The greatest threat of B.1.526 appears to be its ease of spread, with an
estimated transmissibility of ~35% greater than non-variant viruses when competing head-to-head.
Despite the higher observed fitness of B.1.1.7, B.1.526 was able to spread rapidly in the US to
replace other lineages and has continued to increase in frequency in several states. This apparent
increased transmissibility is of particular concern, especially given the relative antibody resistance
of the sub-lineage with the E484K mutation (Fig. 3c). While B.1.1.7 may be the most transmissible
variant identified to date and B.1.351 may pose the greatest antigenic challenge to antibodies and
vaccines, B.1.526 is concerning because it has worrisome features of both. Overall, the
identification of B.1.526 reported here serves to highlight the need for concerted local, national,
and international surveillance programs to track and contain the spread of novel SARS-CoV-2
variants.

References

1. Rambaut, A. *et al. Preliminary genomic characterisation of an emergent SARSCoV-2 lineage in the UK defined by a novel set of spike mutations.* , <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563> (2020).

2. Tegally, H. *et al.* Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *medRxiv*, 2020.2012.2021.20248640, doi:10.1101/2020.12.21.20248640 (2020).

3. Faria, N. R. *et al.* Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. (2021).

4. Wang, P. *et al.* Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. *Nature*, doi:10.1038/s41586-021-03398-2 (2021).

5. Duchene, S. *et al.* Temporal signal and the phylodynamic threshold of SARS-CoV-2. *Virus Evol* **6**, veaa061, doi:10.1093/ve/veaa061 (2020).

6. Cherian, S. *et al.* Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. *bioRxiv*, 2021.2004.2022.440932, doi:10.1101/2021.04.22.440932 (2021).

7. Iacobucci, G. Covid-19: New UK variant may be linked to increased death rate, early data indicate. *BMJ* **372**, n230, doi:10.1136/bmj.n230 (2021).

8. Volz, E. *et al.* Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. *medRxiv*, 2020.2012.2030.20249034, doi:10.1101/2020.12.30.20249034 (2021).

9. Washington, N. L. *et al.* Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. *medRxiv*, doi:10.1101/2021.02.06.21251159 (2021).

10. Greaney, A. J. *et al.* Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe* **29**, 463-476 e466, doi:10.1016/j.chom.2021.02.003 (2021).

11. Thorne, L. G. *et al.* Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant. *bioRxiv*, 2021.2006.2006.446826, doi:10.1101/2021.06.06.446826 (2021).

12. Fujino, T. *et al.* Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan. *Emerg Infect Dis* **27**, doi:10.3201/eid2704.210138 (2021).

13. Faria, N. R. *et al.* Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science*, doi:10.1126/science.abh2644 (2021).

14. Sabino, E. C. *et al.* Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. *Lancet* **397**, 452-455, doi:10.1016/S0140-6736(21)00183-5 (2021).

15. Zucman, N., Uhel, F., Descamps, D., Roux, D. & Ricard, J. D. Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report. *Clin Infect Dis*, doi:10.1093/cid/ciab129 (2021).

16. Nonaka, C. K. V. *et al.* Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil. *Emerg Infect Dis* **27**, doi:10.3201/eid2705.210191 (2021).

17   Wadman, M. & Cohen, J. *Novavax vaccine delivers 89% efficacy against COVID-19 in*
U.K.—but   is   less   potent   in   South   Africa,
<https://www.sciencemag.org/news/2021/01/novavax-vaccine-delivers-89-
efficacy348against-covid-19-uk-less-potent-south-africa> (2021).
18   Callaway, E. & Mallapaty, S. Novavax offers first evidence that COVID vaccines protect
people against variants. *Nature* **590**, 17, doi:10.1038/d41586-021-00268-9 (2021).
19   Madhi, S. A. *et al.* Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the
B.1.351 Variant. *N Engl J Med*, doi:10.1056/NEJMoa2102214 (2021).
20   Wang, P. *et al.* Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody
Neutralization. *bioRxiv*, doi:10.1101/2021.03.01.433466 (2021).
21   Miller, E. H. *et al.* Pretest Symptom Duration and Cycle Threshold Values for Severe
Acute Respiratory Syndrome Coronavirus 2 Reverse-Transcription Polymerase Chain
Reaction Predict Coronavirus Disease 2019 Mortality. *Open Forum Infectious Diseases*
8, doi:10.1093/ofid/ofab003 (2021).
22   West, A. P., Barnes, C. O., Yang, Z. & Bjorkman, P. J. SARS-CoV-2 lineage B.1.526
emerging in the New York region detected by software utility created to query the
spike   mutational   landscape.   *bioRxiv*,   2021.2002.2014.431043,
doi:10.1101/2021.02.14.431043 (2021).
23   WHO. *Tracking SARS-CoV-2 Variants*, <https://www.who.int/en/activities/tracking-
SARS-CoV-2-variants/> (2021).
24   Goudsmit, J., De Ronde, A., Ho, D. D. & Perelson, A. S. Human immunodeficiency virus
fitness in vivo: calculations based on a single zidovudine resistance mutation at codon
215 of reverse transcriptase. *J Virol* **70**, 5662-5664, doi:10.1128/JVI.70.8.5662-
5664.1996 (1996).
25   Ali, S. T. *et al.* Serial interval of SARS-CoV-2 was shortened over time by
nonpharmaceutical   interventions.   *Science*   **369**,   1106-1109,
doi:10.1126/science.abc9004 (2020).
26   Cerutti, G. *et al.* Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-
Terminal Domain Target a Single Supersite. *bioRxiv*, 2021.2001.2010.426120,
doi:10.1101/2021.01.10.426120 (2021).
27   Liu, L. *et al.* Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2
spike. *Nature* **584**, 450-456, doi:10.1038/s41586-020-2571-7 (2020).
28   CDC. *SARS-CoV-2 Variant Classifications and Definitions*, <SARS-CoV-2 Variant
Classifications and Definitions> (2021).
29   Health, N. Y. C. D. o. *COVID-19: Data*, <https://www1.nyc.gov/site/doh/covid/covid-
19-data-trends.page#antibody> (2021).
30   Lasek-Nesselquist, E., Lapierre, P., Schneider, E., George, K. S. & Pata, J. The localized
rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York
State. *medRxiv*, 2021.2002.2026.21251868, doi:10.1101/2021.02.26.21251868
(2021).
31   Alaa Abdel Latif, K. G., Julia L. Mullen, Emily Haag, Ginger Tsueng, Nate Matteson, Mark
Zeller, Chunlei Wu, Kristian G. Andersen, Andrew I. Su, Laura D. Hughes, and the
Center for Viral Systems. *B.1.526 Lineage Report.* , <https://outbreak.info/situation-
reports/S-E484K> (2021).

32 Smyrlaki, I. *et al.* Massive and rapid COVID-19 testing is feasible by extraction-free
SARS-CoV-2 RT-PCR. *Nat Commun* **11**, 4812, doi:10.1038/s41467-020-18611-5
(2020).
33 Quick, J. *Artic Protocol*, <https://www.protocols.io/view/ncov-2019-sequencing-
protocol-v3-locost-bh42j8ye> (2021).
34 Freed, N., Vlkova, M., Faisal, M. B. & Silander, O. Rapid and inexpensive whole-genome
sequencing of SARS-CoV2 using 1200 bp tiled amplicons and Oxford Nanopore rapid
barcoding. *bioRxiv*, doi:10.1101/2020.05.28.122648 (2020).
35 Hadfield, J. *et al.* Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics*
34, 4121-4123, doi:10.1093/bioinformatics/bty407 (2018).
36 Minh, B. Q. *et al.* IQ-TREE 2: New Models and Efficient Methods for Phylogenetic
Inference in the Genomic Era. *Mol Biol Evol* **37**, 1530-1534,
doi:10.1093/molbev/msaa015 (2020).
37 Sagulenko, P., Puller, V. & Neher, R. A. TreeTime: Maximum-likelihood phylodynamic
analysis. *Virus Evol* **4**, vex042, doi:10.1093/ve/vex042 (2018).
38 Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from
vision to reality. *Euro Surveill* **22**, doi:10.2807/1560-7917.ES.2017.22.13.30494
(2017).
39 Pinto, D. *et al.* Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV
antibody. *Nature* **583**, 290-295, doi:10.1038/s41586-020-2349-y (2020).
40 Zost, S. J. *et al.* Rapid isolation and profiling of a diverse panel of human monoclonal
antibodies targeting the SARS-CoV-2 spike protein. *Nat Med* **26**, 1422-1427,
doi:10.1038/s41591-020-0998-x (2020).
41 Robbiani, D. F. *et al.* Convergent antibody responses to SARS-CoV-2 in convalescent
individuals. *Nature* **584**, 437-442, doi:10.1038/s41586-020-2456-9 (2020).
42 Rambaut, A. *et al.* A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist
genomic epidemiology. *Nat Microbiol* **5**, 1403-1407, doi:10.1038/s41564-020-0770-
5 (2020).
364

Figure 1. Prevalence of E484K-harboring SARS-CoV-2 and B.1.526. (a) Detection of viruses

with key signature mutations in spike over time. The earliest detected E484K-harboring variant

was collected in mid-November 2020. The prevalence of E484K ($n_{E484K}/(n_{screened} + n_{E484K})$)

subsequently increased over time, from 4.8% in early December 2020 up to 24.3% in early March

2021. Throughout late 2020 and early 2021, we identified fewer N501Y- than E484K-harboring

isolates, with a maximum of 5.9% of N501Y during mid-February 2021. **(b)** Distribution of

different viral lineages identified by whole genome sequencing. Within our genomic collection

(n=1,210), the B.1.526 lineage rose rapidly in early 2021, replacing the majority of non-variant

lineages (shown as the white blank space) present during this timeframe. This was followed by a

steady rise in B.1.1.7 by mid-2021. The marking below the X axis denotes the time period used to

calculate the growth advantage of B.1.526 over non-variant viruses. **(c)** Phylogenetic tree of

SARS-CoV-2 variants identified by sequencing and alignment of key spike mutations. Unique

patterns of spike protein mutations present in genomes sequenced from our hospital center with at

least one mutation of interest or concern (E484K, N501Y, S477N, or L452R; n=64) are shown.

Residues at which at least one sample harbored a mutation are displayed above the S-protein

schematic.

Figure 2. Spike protein amino acid substitutions and structural changes represented in sequenced isolates. Three amino acid changes are characteristic of the B.1.526 lineage: L5F, T95I, D253G with sub-lineages possessing additional changes S477N, E484K, A701V and Q957R. **(a)** Maximum-likelihood phylogenetic tree of 2309 SARS-CoV-2 viruses colored according to spike protein haplotype. Spike protein mutations are labeled on the tree showing the stepwise

accumulation of signature B.1.526 mutations and branching of the B.1.526-E484K and B.1.526-

S477N sub-lineages. An interactive version of this figure is available at

https://nextstrain.org/groups/blab/ncov/ny/B.1.526. **(b)** Key mutations of B.1.526 displayed on the

spike trimer. The D253G mutation resides in the antigenic supersite within the N-terminal domain

(NTD), a target for neutralizing antibodies, E484K and S477N at the receptor binding domain

(RBD) interface with the cellular receptor ACE2, and A701V near the furin cleavage site.

Figure 3. Neutralization studies of B.1.526-E484K and comparative analyses. (a) Neutralizing

activities of 12 monoclonal antibodies against pseudoviruses containing E484K alone or all five

signature B.1.526 mutations (L5F, T95I, D253G, A701V, and E484K), termed NYΔ5(E484K) as

well as against the authentic B.1.526-E484K. Antibodies with emergency use authorization are

shown in bold solid lines. **(b)** Neutralizing activities of convalescent plasma (n=20) and vaccinee

sera (n=22) against the NYΔ5(E484K) pseudovirus compared to wildtype pseudovirus as well as

against authentic B.1.526-E484K and wildtype virus (WA1). **(c)** Fold change in convalescent

plasma and vaccinee sera neutralization ID50 of different variant pseudoviruses and live viruses

compared to wildtype counterparts. The data on B.1.1.7, B.1.351 and P.1 were derived from our

prior publications[4,20]. Data from 20 convalescent patients or 22 vaccinated individuals were

averaged and are represented as arithmetic mean ± SEM.

Figure 4. Spread of lineages B.1.1.7 and B.1.526 in New York and the USA. (a, b) Frequencies of lineages B.1.1.7 (blue) and B.1.526 (yellow) in the CUIMC catchment area (in panel a) and New York State (in panel b) with dots representing daily 7-day sliding window averages and lines representing fit to a multinomial logistic regression model. **(c)** Ternary plot of state-level frequency trajectories for 42 states separating frequencies of B.1.1.7, B.1.526 and other lineages. Each state-level trajectory is a line in this plot moving from lower left in January 2021 when both B.1.1.7 and B.1.526 were rare, rightward as B.1.1.7 and B.1.526 increase in frequency. The trajectory of New York State is highlighted in purple. **(d)** The same data as in panel c, except plotting frequency of B.1.1.7 against logistic growth rate of B.1.526. (e) Phylogenetic tree of 933 B.1.526 samples from across the US where branch tips are colored based on location of sampling and branches are colored by inferred ancestral location. (f) Phylogeographic view of data from panel e, where each sampling location is represented as a circle with area proportional to sample count and each inferred transition event across the phylogeny is drawn as an arc connecting inferred origin and destination. Most migration events are inferred to be direct dispersals from New York State.

Methods

Clinical cohort. This observational study took place at an academic quaternary care center in New York City. Nasopharyngeal swabs obtained as part of routine clinical care were tested by the Clinical Microbiology laboratory, and positive specimens were transferred to the Columbia University Biobank for inactivation and storage. Electronic health records data extracted for this analysis included demographics, laboratory results, admission, discharge, and transfer dates, current and historical international classification of disease (ICD 9 and 10) codes extracted from the clinical data warehouse. This study was reviewed and approved by the Columbia University Institutional Review Board (protocol number AAAT0123).

PCR screening. Extended Data Figure 1 describes our overall protocol for variant screening. To enable rapid PCR-based screening, we prepared RNA using the heat inactivation method in place of RNA isolation methods[32]. First, 50 µl of nasal swab sample in VTM solution was transferred into 96-well PCR plates, covered with an adhesive aluminum foil (VWR 60941-076) and incubated at 95°C for 5 min using the PCR instrument. After the centrifugation of the plate at >2,100 x g for 5 min, 5 µl of the supernatant from each sample, which contains viral RNA, was used for the SNP assay.

The SNP assay consists of four steps as follows: reverse transcription (RT) of viral RNA, pre-read of the SNP assay, real-time PCR and post-read of the SNP assay. 5 µl of RNA from the supernatant was added to 15 µl of the single step RT-qPCR reaction mix, which consists of 5 µl of TaqPath 1-step RT-qPCR Master Mix, CG (4x) (ThermoFisher Scientific), 500 nM of forward and reverse primers, 120 nM of VIC-MGB probe, 50 nM of FAM-MGB probe, 1/2000 volume of ROX Reference Dye (Invitrogen) as the final concentration, and nuclease-free water to adjust the total reaction volume of 20 µl. Each reaction plate included 8 control wells, $5x10^6$ and $5x10^3$ copies of WA-1 (wild type), UK variant and South African variant, which were generated by PCR to match the variant sequences, and 2 wells with water as no template controls (NTC).

The primer pairs and probes used are as follows. For the SNP assay for position **501**, a primer pair of 501.F: 5'- GGT TTT AAT TGT TAC TTT CCT TTA CA-3' and 501.R: 5'-AGT TCA AAA GAA AGT ACT ACT ACT CTG TAT G-3' were used with two TaqMan probes

(ThermoFisher Scientific), one for wild type, VIC.N501MGB: [VIC]-AA CCC ACT AAT

GGT-MGBNFQ and the other for variant type, FAM.Y501MGB: [FAM]-AAC CCA CTT ATG

GT-MGBNFQ. For position **484**, a primer pair of 484.F: 5'-AGA GAG ATA TTT CAA CTG

AAA TCT ATCAGG-3'and 484.R: 5'-GAA ACC ATA TGA TTG TAA AGG AAA GTA AC-

3' were used with two probes, one for wild type, VIC.E484MGB: [VIC]-ATG GTG TTG AAG

GT-MGBNFQ and the other for variant type, FAM.K484MGB: [FAM]-ATG GTG TTA AAG

GT-MGBNFQ. For position **477**, the primer pair of 477.F and 477.R was used with two probes,

one for wild type, VIC.S477MGB: [VIC]-TTA CAA GGT GTG CTA CCG-MGBNFQ and the

other for variant type, FAM.N477MGB: [FAM]-TTA CAA GGT GTG TTA CCG-MGBNFQ.

The reaction plate was subjected to 1) reverse-transcription reaction (RT) at the condition at 25°C

for 2 min, at 50°C for 15 min and a hold at 4°C; 2) SNP assay (pre-read) at 60°C for 30 sec; 3)

real-time PCR at 95°C for 20 sec followed by 50 cycles of two-step PCR, at 95°C for 3 sec and at

60°C for 30 sec with the fast 7500 mode; followed by 4) SNP assay (post-read) at 60°C for 30 sec

using ABI 7500 Fast Dx Real-Time PCR Instrument with SDS Software (ThermoFisher

Scientific). The genotype at each key position for each sample was determined by reading the

component signal of the amplification and the allelic discrimination analysis software in the

program.

Whole genome sequencing. Extended Data Fig. 2 displays a flowchart outlining samples available

for this study. Isolates with cycle threshold (Ct) values below 35 were selected for sequencing

using the ARTIC v3 low-cost protocol targeting 400bp amplicons[33] or Rapid Barcoding kit

protocol targeting 1,200bp amplicons[34]. Briefly, RNA was extracted using the Qiagen RNeasy

Mini kit or Zymo DNA/RNA Mini kit. Reverse transcription was performed using LunaScript RT

SuperMix (NEB). Tiling PCR was performed on the cDNA, and amplicons were barcoded using

the Oxford Nanopore Native Barcoding Expansion 96 kit. Pooled barcoded libraries were then

sequenced on an Oxford Nanopore MinION sequencer using R9.4.1 flow cells. Basecalling was

performed in the MinKNOW software v21.02.1. Sequencing runs were monitored in real-time

using RAMPART (https://artic-network.github.io/rampart/) to ensure sufficient genomic coverage

with minimal runtime. Consensus sequence generation was performed using the ARTIC

bioinformatics pipeline (https://github.com/artic-network/artic-ncov2019). Genomes were

manually curated by visually inspecting sequencing alignment files for verification of key residues

in Geneious v10.2.6.

Phylogenetic analysis. Phylogenetic reconstruction of amino acid changes (Fig. 2A) was

conducted using the Nextstrain[35] workflow at https://github.com/nextstrain/ncov which aligns

sequences   against   the   Wuhan-Hu-1   reference   via   nextalign

(https://github.com/nextstrain/nextclade), constructs a maximum-likelihood phylogenetic tree via

IQ-TREE[36], estimates molecular clock branch lengths via TreeTime[37] and reconstructs nucleotide

and amino acid changes also via TreeTime. This workflow was applied to 2309 SARS-CoV-2

genomes possessing the 9bp deletion Δ106-108 in ORF1a-nsp6 along with mutation A20262G

which demarcates the parent clade to lineage B.1.526 alongside 688 global reference viruses. This

analysis was conducted on data downloaded from gisaid.org[38] on April 5, 2021. Phylogeographic

reconstruction of spread from New York state (Fig. 4E-F) was similarly conducted using the same

Nextstrain workflow with the addition of performing ancestral trait reconstruction of the

geographic "division" attribute of 933 SARS-CoV-2 genomes downloaded from gisaid.org on Jun

6, 2021.

Neutralization studies of pseudoviruses. We assayed the neutralizing activity of monoclonal

antibodies (mAbs), convalescent plasma, and vaccinee sera against E484K, S477N, and WT

(D614G) pseudoviruses, as well as pseudovirus NYΔ5 containing all five signature mutations of

B.1.526-E484K (L5F, T95I, D253G, E484K, D614G, A701V), as previously described[27]. We

examined four mAbs with emergency use authorization (CB6, REGN10987, REGN10933 and

LY-CoV555), plus eight additional RBD mAbs, including ones from our own collection (2-15, 2-

7, 1-57, & 2-36)[27] as well as S309[39], COV2-2196 & COV2-2130[40], and C121[41], We also examined

convalescent plasma collected in Spring of 2020 (n=20 patients), and Moderna and Pfizer vaccinee

sera (n=22)[4]. Briefly, Vero E6 cells (ATCC) were seeded in 96-well plates (2×10^4 cells per well).

Pseudoviruses were incubated with serial dilutions of the test samples in triplicate for 30 min at

37 °C. The mixture was added to cultured cells and incubated for an additional 24 h. Luminescence

was measured using a Britelite plus Reporter Gene Assay System (PerkinElmer), and IC_{50} was

defined as the dilution at which the relative light units were reduced by 50% compared with the

virus control wells (virus + cells) after subtraction of the background in the control groups with

cells only. The IC$_{50}$ values were calculated using nonlinear regression in GraphPad Prism 8.0.

Statistical analysis was performed using a Wilcoxon matched-pairs signed rank test. Two-tailed p-

values are reported.

Neutralization of infectious SARS-CoV-2. Infectious SARS-CoV-2 isolate hCoV-19/USA/NY-

NP-DOH1/2021 was isolated at the Aaron Diamond AIDS Center (Columbia University Medical

Ctr) from nasopharyngeal swab and propagated for one passage in Vero E6 cells (ATCC).

Infectious titer of the resulting virus was determined by an end-point dilution and cytopathic effect

(CPE) assay on Vero-E6 cells as described previously[27]. The virus has since been deposited at BEI

Resources (Cat#NR-55359). SARS-CoV-2 virus USA-WA1/2020 (WA1) obtained from BEI

Resources (Cat# NR-52281) served as the control in experiments.

An end-point dilution microplate neutralization assay was performed to measure the neutralization

activity of twenty patient convalescent plasma samples and twelve purified monoclonal antibodies.

In brief, plasma samples were subjected to successive 5-fold dilutions starting from 1:100.

Similarly, antibodies were serially diluted (5-fold dilutions) starting at 50 µg/ml. Triplicates of

each dilution were incubated with SARS-CoV-2 at an MOI of 0.1 in EMEM with 7.5% inactivated

fetal calf serum (FCS) for 1 hour at 37°C. Post incubation, the virus-antibody mixture was

transferred onto a monolayer of Vero-E6 cells grown overnight. The cells were incubated with

the mixture for ~70 hours. Cytopathic effect (CPE) of viral infection was visually scored for each

well in a blinded fashion by two independent observers. The results were then converted into

percentage neutralization at a given sample dilution or antibody concentration, and the averages ±

SEM were plotted using a five-parameter dose-response curve in GraphPad Prism v8.4.

Growth dynamics. Growth dynamics of B.1.1.7 and B.1.526 were obtained through by

downloading "metadata" from gisaid.org on June 6, 2021 for all 422,760 viruses sampled from the

USA collected after January 1, 2021. This metadata has PANGO lineages[42] already assigned to

each genome sequence. Daily state-level frequencies (and frequencies for CUIMC) were extracted

for plotting via 7-day sliding window averages of the prevalence of B.1.1.7 and B.1.526, calculated

as the number of sequence-verified samples from each strain divided by the total number of

positive samples with cycle threshold (Ct) values below 35, as this threshold value was used for

sequencing. Separately, a multinomial logistic regression model was fit directly to the observation

data consisting of individual genomes, their dates of sampling (independent variable X in days

since January 1, 2021) and their categorical labels (dependent variable Y, "B.1.1.7", "B.1.526" and

"other"). This results in a 4-parameter model where both B.1.1.7 and B.1.526 have parameters

specified for frequency at day 0 (January 1, 2021) and logistic growth rate. This model was fit to

the data using the Classify package of Mathematica v12.2.

Data availability. All genomes and associated metadata generated as a part of this study have been

uploaded to GISAID. Biological materials (i.e. variant pseudoviruses) generated as a part of this

study will be made available but may require execution of a materials transfer agreement.

Code availability. Data processing and visualization was performed using publicly available

software and packages, primarily RStudio v1.2.5033, GraphPad Prism v8.4, and iTOL

(https://itol.embl.de/). The exact workflow used for phylogenetic (Fig. 2A) and phylogeographic

analysis of public GISAID data (Fig. 4E-F) is available at https://github.com/blab/ncov-ny.

Frequency dynamics were modeled using Mathematica in notebooks also available at

https://github.com/blab/ncov-ny.

Methods References

32   Smyrlaki, I. et al. Massive and rapid COVID-19 testing is feasible by extraction-free

SARS-CoV-2 RT-PCR. Nat Commun 11, 4812, doi:10.1038/s41467-020-18611-5 (2020).

33   Quick, J. Artic Protocol, <https://www.protocols.io/view/ncov-2019-sequencing-protocol-

v3-locost-bh42j8ye> (2021).

34   Freed, N., Vlkova, M., Faisal, M. B. & Silander, O. Rapid and inexpensive whole-genome

sequencing of SARS-CoV2 using 1200 bp tiled amplicons and Oxford Nanopore rapid

barcoding. bioRxiv, doi:10.1101/2020.05.28.122648 (2020).

35   Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34,

4121-4123, doi:10.1093/bioinformatics/bty407 (2018).

36   Minh, B. Q. et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic

Inference in the Genomic Era. Mol Biol Evol 37, 1530-1534, doi:10.1093/molbev/msaa015

(2020).

37   Sagulenko, P., Puller, V. & Neher, R. A. TreeTime: Maximum-likelihood phylodynamic
analysis. Virus Evol 4, vex042, doi:10.1093/ve/vex042 (2018).
38   Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from
vision to reality. Euro Surveill 22, doi:10.2807/1560-7917.ES.2017.22.13.30494 (2017).
39   Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV
antibody. Nature 583, 290-295, doi:10.1038/s41586-020-2349-y (2020).
40   Zost, S. J. et al. Rapid isolation and profiling of a diverse panel of human monoclonal
antibodies targeting the SARS-CoV-2 spike protein. Nat Med 26, 1422-1427,
doi:10.1038/s41591-020-0998-x (2020).
41   Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent
individuals. Nature 584, 437-442, doi:10.1038/s41586-020-2456-9 (2020).
42   Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist
genomic epidemiology. Nat Microbiol 5, 1403-1407, doi:10.1038/s41564-020-0770-5
(2020).

Acknowledgements: Biospecimens utilized for this research were obtained from the Columbia
University Biobank (CUB) with technical support from Viplan J. Mahadeva, Sebastian
Fernando and Sylvia T. Parker-Jones. CUB is supported by the Irving Institute for Clinical and
Translational Research (NCATS UL1TR001873). In particular, we thank Muredach Reilly, Eldad
Hod, and the CUB COVID-19 Genomics Consortium (CCGC) for facilitating this effort. We are
also grateful to Lihong Liu and Sho Iketani for technical support, and Alan Perelson for
mathematical input. We gratefully acknowledge all the authors, the originating laboratories
responsible for obtaining the specimens, and the submitting laboratories for generating the genetic
sequence and metadata and sharing via the GISAID Initiative, on which part of the presented
research is based (see Supplementary Table 1). This work was in part funded by NIH/NIDA grant
U01 DA053949 (A.-C.U, M.K.A.) and by support from Andrew & Peggy Cherng, Samuel Yin,
Barbara Picower and the JBP Foundation, Brii Biosciences, Roger & David Wu, and the Bill and
Melinda Gates Foundation. T.B. is a Pew Biomedical Scholar and is supported by NIH grant no.
R35 GM119774-01. Funders and funding agencies had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.

Competing Interests: P.W., M.S.N., Y.H., and D.D.H. are inventors on a provisional patent application on monoclonal antibodies against SARS-CoV-2. D.D.H. is a member of the scientific advisory board of Brii Biosciences, which has provided a grant to Columbia University to support this and other studies on SARS-CoV-2. A.-C.U. and D.D.H. have received funding from Merck & Co. unrelated to this study.

Author Contributions: Conceptualization – A.-C.U., D.D.H., M.K.A., H.M.; **Data curation** – M.K.A., H.M., J.E.Z., P.W., M.S.N., Z.S., T.B., A.G.-S., Y.H., A.L.K., M.T., A.-C.U.; **Formal analysis** – M.K.A., P.W., J.E.Z., T.B., A.G.-S.; **Funding acquisition** – A.-C.U., D.D.H., M.K.A.; **Investigation** – M.K.A., H.M., J.E.Z., P.W., M.S.N., A.L.K., M.T., T.B., Y.H.; **Methodology** – M.K.A., H.M., P.W., M.S.N., T.B., Y.H.; **Supervision** – A.-C.U., D.D.H.; **Visualization** – M.K.A., P.W., T.B.; **Writing – original draft** – A.-C.U., M.K.A., H.M., D.D.H.; **Writing – review and editing** – all authors

Supplementary Information is available for this paper.

Correspondence and requests for materials should be addressed to Anne-Catrin Uhlemann (au2110@cumc.columbia.edu) or David D. Ho (dh2994@cumc.columbia.edu).

 Extended Data

Extended Data Table 1. Clinical characteristics of patients infected with SARS-CoV-2 based on viral genotype

Clinical Characteristic	E484K (n=148)	Wildtype [1] (n=1,124)	P [2]	B.1.526-E484K (n=192)	Non-VOI/VOC lineages [1] (n=660)	P [2]
Demographics						
Male sex, n (%)	71 (48.0)	507 (45.1)	0.575	81 (42.2)	316 (48.0)	0.179
Age, years (median [IQR])	58 [38, 71]	55 [32, 71]	0.354 [3]	49 [32, 71]	52 [30, 68]	0.778 [3]
Race and ethnicity, n (%)			0.524			0.562
Hispanic/Latino	74 (50.0)	520 (46.3)		99 (51.6)	304 (46.2)	
Black	11 (7.4)	122 (10.9)		21 (10.9)	74 (11.2)	
White	19 (12.8)	164 (14.6)		21 (10.9)	90 (13.7)	
Other	44 (29.7)	317 (28.2)		51 (26.6)	190 (28.9)	
Place of residence, n (%)			0.017			0.011
NYC	129 (87.2)	909 (80.9)		166 (86.5)	521 (78.9)	
Yonkers	7 (4.7)	31 (2.8)		8 (4.2)	19 (2.9)	
Outside NYC and Yonkers	12 (8.1)	184 (16.4)		18 (9.4)	120 (18.2)	
Comorbidities						
BMI, kg/m2 (median [IQR])	28.6 [24.9, 33.5]	27.3 [23.4, 31.4]	0.064 [3]	28.4 [24.3, 33.1]	26.5 [23.0, 30.1]	0.008 [3]
Hypertension, n (%)	66 (45.2)	424 (41.4)	0.435	73 (39.5)	243 (40.5)	0.868
Diabetes mellitus, n (%)	47 (32.2)	247 (24.1)	0.045	57 (30.8)	130 (21.7)	0.014
Chronic kidney disease, n (%)	19 (13.0)	113 (11.0)	0.571	15 (8.1)	79 (13.2)	0.085
Coronary artery disease, n (%)	12 (8.2)	97 (9.5)	0.737	13 (7.0)	52 (8.7)	0.579
Solid organ transplant, n (%)	4 (2.7)	38 (3.7)	0.725	7 (3.8)	35 (5.8)	0.370
Cycle threshold value (mean (SD)) [4]	29.49 (5.57)	30.71 (5.64)	0.013	27.33 (4.57)	28.31 (4.74)	0.041
Severity of care and outcomes						
Highest level of care, n (%)			0.281			0.041
Admitted	48 (32.4)	393 (35.1)		69 (35.9)	185 (28.2)	
Emergency Department	55 (37.2)	321 (28.6)		65 (33.9)	201 (30.6)	
ICU	11 (7.4)	86 (7.7)		12 (6.2)	52 (7.9)	
Outpatient	34 (23.0)	320 (28.5)		46 (24.0)	219 (33.3)	
Supplemental oxygen, n (%)	46 (86.8)	327 (76.2)	0.118	55 (79.7)	155 (71.4)	0.230
Outcome, n (%)			0.293			0.482
Deceased or discharged to hospice	7 (4.7)	86 (7.7)		8 (4.2)	37 (5.6)	
Further care at external facility	15 (10.1)	76 (6.8)		15 (7.9)	38 (5.8)	
Discharged to home	126 (85.1)	956 (85.4)		167 (87.4)	579 (88.4)	

[1] Wildtype isolates are defined as those without E484K or N501Y mutations. For comparisons based on lineage, B.1.526-E484K was compared with non-variant of interest (VOI) and non-variant of concern (VOC) lineages (i.e. B.1.526.1, B.1.526.2, B.1.1.7, P.1, P.2, and B.1.351 were excluded)

[2] T-tests were performed for continuous variables and chi-squared tests for categorical variables, unless otherwise indicated as below

[3] Due to non-normal distribution, Kruskal-Wallis non-parametric test was used

[4] Cycle threshold value as determined through our rapid qPCR-based screening assay on heat-inactivated nasopharyngeal swab samples

Extended Data Figure 1. Rapid PCR-based screening assay protocol to identify samples harboring key substitutions. (a) Viral RNA is prepared by heat inactivation and centrifugation. The supernatant is then used for the SNP assay, which entails four steps: the reverse transcription (RT) reaction, pre-PCR reading of the plate to assess background fluorescence (SNP pre-read), real-time PCR, and post-PCR reading of the plate to measure fluorescence (SNP post-read). The runtime for this entire protocol is approximately two hours. (b) Genotype at targeted sites in COVID-19 viral RNA can be determined with two MGB probes, one for wild type (conjugated with VIC) and the other for variant type (conjugated with FAM). (c) Example signals for the variant type (K484; blue), the wild type (E484; red) and samples with no signal (black) are shown.

Note: 1 swab identified with E484K and
N501Y was sequence-verified as B.1.351

**Extended Data Figure 2. Flowchart for SARS-CoV-2-positive nasopharyngeal swabs
included in this study.** (**top**) During the study period of November 1, 2020 to May 1, 2021,
6,680 patients tested positive for SARS-CoV-2 at our hospital center and affiliated hospitals.
From these 9,174 positive nasopharyngeal swabs, 3,433 swabs were stored as part of the
Columbia University Biobank effort to archive samples during the COVID-19 pandemic. (**left**)
PCR-based genotyping assays for E484K and N501Y (see Extended Data Fig. 1) were performed
on 2,174 samples collected in the early phase of this study, between November 1, 2020 and
March 1, 2021. We identified a significant proportion of samples with E484K (10.8%), later
confirmed through sequencing to primarily fall within the B.1.526 lineage, and a number of
samples with N501Y (2.9%), primarily within the B.1.1.7 lineage. (**right**) We performed whole-
genome sequencing on 1,210 samples during the full study period, until May 1, 2020. Of these,
32.5% belonged to B.1.562 and the sublineages B.1.526.1 and B.1.526.2, while B.1.1.7
constituted a much smaller proportion of samples at our center (8.8%).

Extended Data Figure 3. Neutralization studies of B.1.526-S477N. (a) Neutralizing activities of 12 monoclonal antibodies against pseudoviruses containing S477N alone or all five signature B.1.526-S477N mutations (L5F, T95I, D253G, A701V, and S477N), termed NYΔ5(S477N). Antibodies with emergency use authorization are shown in bold solid lines. **(b)** Neutralizing activities of convalescent plasma (n=20) against NYΔ5(S477N) as well as against the authentic B.1.526 virus with S477N, and neutralizing activities of vaccinee sera (n=22) against the NYΔ5(S477N) pseudovirus, compared to wildtype counterparts.

636
637
Extended Data Figure 4. State-level growth dynamics of B.1.526 and B.1.1.7. Daily state-level
frequencies of B.1.526 (in yellow) and B.1.1.7 (in blue), based on GISAID data downloaded on
June 6, 2021, were used to plot 7-day sliding window averages of the prevalence of each lineage
(shown as dots in the figure). A 4-parameter multinomial logistic regression model was fit directly
to the observation data, in which both B.1.1.7 and B.1.526 have parameters specified for frequency
at day 0 (January 1, 2021) and logistic growth rate (shown as lines in the figure). States are ordered
according to frequency of B.1.526 at the final timepoint of May 8, 2021.